Competing interests
AN, CS, CW, ET, HY, JFC, JM, LM, MHS, MTN, MZ, NF, SJY, and VA declare no conflicts of interest. AAP: Research Funding: Sumitomo, Pfizer, Incyte, Servier, Stemline. Honoraria: AbbVie, Amgen, Astellas, Cycle, Geron, Jazz, Novartis, Sobi, Syndax, Refined Oncology. Data Safety Monitoring Committee: Takeda. MFB and KP are co-founders and directors of Voronoi Health Analytics, Inc. (Vancouver, British Columbia, Canada), a medical imaging software company specializing in AI-powered body composition analysis. Statistical analyses and interpretation of study outcomes were conducted independent of these investigators to guard against conflict of interest. OO discloses research funding (paid to institution) from AbbVie, AstraZeneca, Celgene, Curis, Incyte, Shattuck Labs, and K-Group Alpha; scientific advisory board participation for AbbVie, Celgene/Bristol Myers Squibb, Novartis, Incyte, Kymera Therapeutics, Servier, and Rigel; and service on data safety board for Treadwell Therapeutics. RAL has acted as a consultant or advisor to Ascentage Pharma, CVS/Caremark, Epizyme/Ipsen, and Novartis, and has received clinical research support to his institution from Ascentage, Astellas, Biomea Fusion, Cellectis, Daiichi Sankyo, and Novartis, and royalties from UpToDate. WS reports consultancy for Newave, Servier.
Ethics approval and consent to participate
The UCCCC Institutional Review Board (IRB00000331) approved the study. All methods were performed in accordance with relevant ethical guidelines and regulations. All subjects provided informed consent.
